Are you over 18 and want to see adult content?
More Annotations
A complete backup of allmobileworld.it
Are you over 18 and want to see adult content?
A complete backup of livrustkammaren.se
Are you over 18 and want to see adult content?
A complete backup of indexjournal.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of shivabalayogi.org
Are you over 18 and want to see adult content?
A complete backup of allergicliving.com
Are you over 18 and want to see adult content?
A complete backup of naumankhawer.wordpress.com
Are you over 18 and want to see adult content?
A complete backup of primaryone2015.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of miniaturasdevictoria.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of newcambridge.net
Are you over 18 and want to see adult content?
Text
ADVISORY BOARD
A suite of web services and tools that make it easier for researchers to aggregate, organize, analyze, and share scientific data, code, and insights. A platform for conducting biomedical research studies primarily using the ResearchKit (iOS) and ResearchStack (Android) frameworks. An open-science, collaborative competition framework forOPEN POSITIONS
Sage Bionetworks is a nonprofit research and technology development organization based in Seattle. We have a flat management structure and we offer competitive salaries, comprehensive benefits (health, dental, life and disability, health savings, 403b retirement plan), vacation time, flexible schedule and the ability to work from home, bike facilities, great coffee (we have a LaAD KNOWLEDGE PORTAL
The AD Knowledge Portal is a platform for accessing data, analyses, and tools that the National Institute on Aging’s (NIA) Alzheimer’s Disease Translational Research Program generates through several initiatives. The program encourages open-science collaborations that share resources early in the research life cycle. The AD Knowledge Portal initially hosted data from the Accelerating TREAT-AD - SAGE BIONETWORKS The overarching purpose of the TREAT-AD program is to improve, diversify and reinvigorate the Alzheimer’s disease (AD) drug development pipeline by accelerating the characterization and experimental validation of next generation therapeutic targets and integrating the targets into drug discovery campaigns. In addition, this program aims to de JUSTIN GUINNEY, VP COMPUTATIONAL ONCOLOGY Justin Guinney is the Vice President of the Computational Oncology group at Sage Bionetworks. His group contains specialists from multiple domains, including molecular biology, computer science, and oncology, and focuses on the development of computational models for optimizing patient diagnosis, prognosis, and treatment in cancer. AGORA - SAGE BIONETWORKS Agora hosts evidence for whether or not genes are associated with Alzheimer’s disease (AD). Agora also contains a list of close to 100 nascent drug targets for AD that were nominated. by AD researchers. The initial list of nominated targets was contributed by researchers from the National Institute on Aging’s Accelerating Medicines Partnership in Alzheimer’sTHE PSORCAST STUDY
The Psorcast Study will be a remote, nationwide observational study to collect multidimensional, high-resolution time-series data from psoriasis patients’ smartphone sensors. The Psorcast app measures symptoms, disease-influencing factors, and outcomes as a foundational dataset for creating personalized forecasts of disease activity. DIGITAL MAMMOGRAPHY DREAM CHALLENGE The goal of the Digital Mammography (DM) DREAM Challenge was to apply an open science, crowd-sourced approach to develop and assess algorithms for risk stratification of screening mammograms that can be used to improve breast cancer detection. These algorithms could potentially benefit interpretation of other tumor imaging, impacting a wide set of cancer patients. The ELEMENTS OF INFORMED CONSENT The Elements of Informed Consent is a toolkit that will help researchers think through what information participants should receive as part of the consenting process in order to make an informed decision about whether or not to join a study. Developed by the Governance Team at Sage Bionetworks, the toolkit shares basic information and best practices for developing an effective consentingprocess.
MULTIPLE MYELOMA DREAM CHALLENGE Multiple myeloma (MM) is a cancer of the plasma cells in the bone marrow, and its clinical course depends on a complex interplay of clinical traits and molecular characteristics of the plasma cells. Since risk-adapted therapy is becoming standard of care, there is an urgent need for a precise risk stratification model to assist in SAGE BIONETWORKS: RESPONSIBLE DATA SHARING, RELIABLE METHODSABOUTHOW WE PARTNERTOOLS & RESOURCESCAREERSBOARD OF DIRECTORSSCIENTIFICADVISORY BOARD
A suite of web services and tools that make it easier for researchers to aggregate, organize, analyze, and share scientific data, code, and insights. A platform for conducting biomedical research studies primarily using the ResearchKit (iOS) and ResearchStack (Android) frameworks. An open-science, collaborative competition framework forOPEN POSITIONS
Sage Bionetworks is a nonprofit research and technology development organization based in Seattle. We have a flat management structure and we offer competitive salaries, comprehensive benefits (health, dental, life and disability, health savings, 403b retirement plan), vacation time, flexible schedule and the ability to work from home, bike facilities, great coffee (we have a LaAD KNOWLEDGE PORTAL
The AD Knowledge Portal is a platform for accessing data, analyses, and tools that the National Institute on Aging’s (NIA) Alzheimer’s Disease Translational Research Program generates through several initiatives. The program encourages open-science collaborations that share resources early in the research life cycle. The AD Knowledge Portal initially hosted data from the Accelerating TREAT-AD - SAGE BIONETWORKS The overarching purpose of the TREAT-AD program is to improve, diversify and reinvigorate the Alzheimer’s disease (AD) drug development pipeline by accelerating the characterization and experimental validation of next generation therapeutic targets and integrating the targets into drug discovery campaigns. In addition, this program aims to de JUSTIN GUINNEY, VP COMPUTATIONAL ONCOLOGY Justin Guinney is the Vice President of the Computational Oncology group at Sage Bionetworks. His group contains specialists from multiple domains, including molecular biology, computer science, and oncology, and focuses on the development of computational models for optimizing patient diagnosis, prognosis, and treatment in cancer. AGORA - SAGE BIONETWORKS Agora hosts evidence for whether or not genes are associated with Alzheimer’s disease (AD). Agora also contains a list of close to 100 nascent drug targets for AD that were nominated. by AD researchers. The initial list of nominated targets was contributed by researchers from the National Institute on Aging’s Accelerating Medicines Partnership in Alzheimer’sTHE PSORCAST STUDY
The Psorcast Study will be a remote, nationwide observational study to collect multidimensional, high-resolution time-series data from psoriasis patients’ smartphone sensors. The Psorcast app measures symptoms, disease-influencing factors, and outcomes as a foundational dataset for creating personalized forecasts of disease activity. DIGITAL MAMMOGRAPHY DREAM CHALLENGE The goal of the Digital Mammography (DM) DREAM Challenge was to apply an open science, crowd-sourced approach to develop and assess algorithms for risk stratification of screening mammograms that can be used to improve breast cancer detection. These algorithms could potentially benefit interpretation of other tumor imaging, impacting a wide set of cancer patients. The ELEMENTS OF INFORMED CONSENT The Elements of Informed Consent is a toolkit that will help researchers think through what information participants should receive as part of the consenting process in order to make an informed decision about whether or not to join a study. Developed by the Governance Team at Sage Bionetworks, the toolkit shares basic information and best practices for developing an effective consentingprocess.
MULTIPLE MYELOMA DREAM CHALLENGE Multiple myeloma (MM) is a cancer of the plasma cells in the bone marrow, and its clinical course depends on a complex interplay of clinical traits and molecular characteristics of the plasma cells. Since risk-adapted therapy is becoming standard of care, there is an urgent need for a precise risk stratification model to assist inPUBLICATIONS
IRB Management and Function, 3rd edition: mHealth, Mobile Devices, and Apps (book chapter) January 17. Open Data Sharing in the 21st Century: Sage Bionetworks’ Qualified Research Program and Its Application in mHealth Data Release. January 8. Crowdsourced mapping of unexplored target space of kinase inhibitors. INTRODUCING NLPSANDBOX.IO By Jiaxin Zheng and Thomas Schaffter Natural language processing, or NLP, is a technology used in many ways to help computers understand human language. This is particularly impactful in biomedical research, where hospitals have millions of unstructured notes they need to de-identify before sharing with researchers. Manually de-identifying them would put significant strain on NEWS & PRESS RELEASES 2017. November 3. Sage Bionetworks is part of a consortium of universities and research groups which has received a five-year, $25 million grant from the National Center for Advancing Translational Science. August 21. Novartis launches first large-scale research study in multiple sclerosis that allows participants to contribute fromsmartphones.
AGORA - SAGE BIONETWORKS Agora hosts evidence for whether or not genes are associated with Alzheimer’s disease (AD). Agora also contains a list of close to 100 nascent drug targets for AD that were nominated. by AD researchers. The initial list of nominated targets was contributed by researchers from the National Institute on Aging’s Accelerating Medicines Partnership in Alzheimer’sOUR CULTURE
Culture Committee – We invest in how we spend our time together - through our culture committee we support employee-led initiatives like our Friday seminar series, board game night, running, hiking and climbing clubs, as well as the Ladies at Sage mentoring program. Objectives – Our performance objectives are organization-wide withdefined
DIGITAL HEALTH ASSESSMENTS The Body Area Draw assessment allows a participant to use the touch screen to draw the extent to which an area of the body is affected by a given symptom. Data collected include the calculated percentage of the body surface area and a jpeg image summary. MULTIPLE MYELOMA DREAM CHALLENGE Multiple myeloma (MM) is a cancer of the plasma cells in the bone marrow, and its clinical course depends on a complex interplay of clinical traits and molecular characteristics of the plasma cells. Since risk-adapted therapy is becoming standard of care, there is an urgent need for a precise risk stratification model to assist inLARA MANGRAVITE
Lara Mangravite, PhD, is President of Sage Bionetworks. Previously, she served as the director of the systems biology research group at Sage, where she focused on the application of collaborative approaches to advance understanding of disease biology and treatment outcomes at a systems level with the overriding goal of improving clinical care. Dr. Mangravite earned DREAM CHALLENGES POWERED BY SAGE BIONETWORKS DREAM Challenges are community competitions that address fundamental questions about systems biology and translational medicine and advance computational methods. Designed and run by a multidisciplinary community of researchers, DREAM challenges invite participants to propose solutions — fostering collaboration and building communities in the process. Expertise and institutional support PARKINSON’S DISEASE DIGITAL BIOMARKER DREAM CHALLENGE Recent advances in mobile health have demonstrated great potential to leverage sensor-based technologies for remote monitoring of health and disease – particularly for diseases affecting motor function such as Parkinson’s disease (PD). However, converting sensor-based data streams into digital biomarkers is complex and no methodological standards have yet evolved to guide this process. The SAGE BIONETWORKS: RESPONSIBLE DATA SHARING, RELIABLE METHODSABOUTHOW WE PARTNERTOOLS & RESOURCESCAREERSBOARD OF DIRECTORSSCIENTIFICADVISORY BOARD
A suite of web services and tools that make it easier for researchers to aggregate, organize, analyze, and share scientific data, code, and insights. A platform for conducting biomedical research studies primarily using the ResearchKit (iOS) and ResearchStack (Android) frameworks. An open-science, collaborative competition framework for WHO WE ARE - SAGE BIONETWORKS Sage Bionetworks is a nonprofit health research organization that was founded in Seattle in 2009. We use open practices that increase the reliability of scientific claims to speed the translation of science to medicine. We support responsible data sharing, objective evaluation of methods and results across researchers, and the empowerment ofOPEN POSITIONS
Sage Bionetworks is a nonprofit research and technology development organization based in Seattle. We have a flat management structure and we offer competitive salaries, comprehensive benefits (health, dental, life and disability, health savings, 403b retirement plan), vacation time, flexible schedule and the ability to work from home, bike facilities, great coffee (we have a LaOUR CULTURE
Culture Committee – We invest in how we spend our time together - through our culture committee we support employee-led initiatives like our Friday seminar series, board game night, running, hiking and climbing clubs, as well as the Ladies at Sage mentoring program. Objectives – Our performance objectives are organization-wide withdefined
TREAT-AD - SAGE BIONETWORKS The overarching purpose of the TREAT-AD program is to improve, diversify and reinvigorate the Alzheimer’s disease (AD) drug development pipeline by accelerating the characterization and experimental validation of next generation therapeutic targets and integrating the targets into drug discovery campaigns. In addition, this program aims to de JUSTIN GUINNEY, VP COMPUTATIONAL ONCOLOGY Justin Guinney is the Vice President of the Computational Oncology group at Sage Bionetworks. His group contains specialists from multiple domains, including molecular biology, computer science, and oncology, and focuses on the development of computational models for optimizing patient diagnosis, prognosis, and treatment in cancer. ALL OF US RESEARCH PROGRAM The mission of the All of Us Research Program is to accelerate health research and medical breakthroughs, enabling individual prevention, treatment, and care solutions. The Digital Health Technology (DHT) effort within All of Us uses technologies like mobile apps and wearable devices to measure and track aspects of lifestyle, environment, and biology. We design and deploy DIGITAL MAMMOGRAPHY DREAM CHALLENGE The goal of the Digital Mammography (DM) DREAM Challenge was to apply an open science, crowd-sourced approach to develop and assess algorithms for risk stratification of screening mammograms that can be used to improve breast cancer detection. These algorithms could potentially benefit interpretation of other tumor imaging, impacting a wide set of cancer patients. The ELEMENTS OF INFORMED CONSENT The Elements of Informed Consent is a toolkit that will help researchers think through what information participants should receive as part of the consenting process in order to make an informed decision about whether or not to join a study. Developed by the Governance Team at Sage Bionetworks, the toolkit shares basic information and best practices for developing an effective consentingprocess.
ICGC-TCGA WHOLE GENOME PAN-CANCER ANALYSIS WORKING GROUP In 2013, Sage assisted with the coordination of The Cancer Genome Atlas (TCGA) pan-cancer analysis by hosting and coordinating the outputs of 65 different analytical workflows using the open source software platform developed by Sage, called Synapse, which data scientists can use to carry out, track, and communicate their research in real time. Since then, SAGE BIONETWORKS: RESPONSIBLE DATA SHARING, RELIABLE METHODSABOUTHOW WE PARTNERTOOLS & RESOURCESCAREERSBOARD OF DIRECTORSSCIENTIFICADVISORY BOARD
A suite of web services and tools that make it easier for researchers to aggregate, organize, analyze, and share scientific data, code, and insights. A platform for conducting biomedical research studies primarily using the ResearchKit (iOS) and ResearchStack (Android) frameworks. An open-science, collaborative competition framework for WHO WE ARE - SAGE BIONETWORKS Sage Bionetworks is a nonprofit health research organization that was founded in Seattle in 2009. We use open practices that increase the reliability of scientific claims to speed the translation of science to medicine. We support responsible data sharing, objective evaluation of methods and results across researchers, and the empowerment ofOPEN POSITIONS
Sage Bionetworks is a nonprofit research and technology development organization based in Seattle. We have a flat management structure and we offer competitive salaries, comprehensive benefits (health, dental, life and disability, health savings, 403b retirement plan), vacation time, flexible schedule and the ability to work from home, bike facilities, great coffee (we have a LaOUR CULTURE
Culture Committee – We invest in how we spend our time together - through our culture committee we support employee-led initiatives like our Friday seminar series, board game night, running, hiking and climbing clubs, as well as the Ladies at Sage mentoring program. Objectives – Our performance objectives are organization-wide withdefined
TREAT-AD - SAGE BIONETWORKS The overarching purpose of the TREAT-AD program is to improve, diversify and reinvigorate the Alzheimer’s disease (AD) drug development pipeline by accelerating the characterization and experimental validation of next generation therapeutic targets and integrating the targets into drug discovery campaigns. In addition, this program aims to de JUSTIN GUINNEY, VP COMPUTATIONAL ONCOLOGY Justin Guinney is the Vice President of the Computational Oncology group at Sage Bionetworks. His group contains specialists from multiple domains, including molecular biology, computer science, and oncology, and focuses on the development of computational models for optimizing patient diagnosis, prognosis, and treatment in cancer. ALL OF US RESEARCH PROGRAM The mission of the All of Us Research Program is to accelerate health research and medical breakthroughs, enabling individual prevention, treatment, and care solutions. The Digital Health Technology (DHT) effort within All of Us uses technologies like mobile apps and wearable devices to measure and track aspects of lifestyle, environment, and biology. We design and deploy DIGITAL MAMMOGRAPHY DREAM CHALLENGE The goal of the Digital Mammography (DM) DREAM Challenge was to apply an open science, crowd-sourced approach to develop and assess algorithms for risk stratification of screening mammograms that can be used to improve breast cancer detection. These algorithms could potentially benefit interpretation of other tumor imaging, impacting a wide set of cancer patients. The ELEMENTS OF INFORMED CONSENT The Elements of Informed Consent is a toolkit that will help researchers think through what information participants should receive as part of the consenting process in order to make an informed decision about whether or not to join a study. Developed by the Governance Team at Sage Bionetworks, the toolkit shares basic information and best practices for developing an effective consentingprocess.
ICGC-TCGA WHOLE GENOME PAN-CANCER ANALYSIS WORKING GROUP In 2013, Sage assisted with the coordination of The Cancer Genome Atlas (TCGA) pan-cancer analysis by hosting and coordinating the outputs of 65 different analytical workflows using the open source software platform developed by Sage, called Synapse, which data scientists can use to carry out, track, and communicate their research in real time. Since then, INTRODUCING NLPSANDBOX.IO By Jiaxin Zheng and Thomas Schaffter Natural language processing, or NLP, is a technology used in many ways to help computers understand human language. This is particularly impactful in biomedical research, where hospitals have millions of unstructured notes they need to de-identify before sharing with researchers. Manually de-identifying them would put significant strain onPUBLICATIONS
IRB Management and Function, 3rd edition: mHealth, Mobile Devices, and Apps (book chapter) January 17. Open Data Sharing in the 21st Century: Sage Bionetworks’ Qualified Research Program and Its Application in mHealth Data Release. January 8. Crowdsourced mapping of unexplored target space of kinase inhibitors. PLATFORMS - SAGE BIONETWORKS Platforms. The Sage Technology Platform is specifically chartered to identify common needs across multiple projects, and to develop general-purpose services and tools that serve the current and future needs of both Sage’s in-house research team, and our external research partners. This development is often facilitated throughcollaboration
AGORA - SAGE BIONETWORKS Agora hosts evidence for whether or not genes are associated with Alzheimer’s disease (AD). Agora also contains a list of close to 100 nascent drug targets for AD that were nominated. by AD researchers. The initial list of nominated targets was contributed by researchers from the National Institute on Aging’s Accelerating Medicines Partnership in Alzheimer’s DIGITAL HEALTH ASSESSMENTS Digital Jar Open. The Digital Jar Open assessment measures the functional range of motion without pain for the joints of the arm (wrist, elbow, shoulder) on each arm while rotating inward andoutward.
AD KNOWLEDGE PORTAL
The AD Knowledge Portal is a platform for accessing data, analyses, and tools that the National Institute on Aging’s (NIA) Alzheimer’s Disease Translational Research Program generates through several initiatives. The program encourages open-science collaborations that share resources early in the research life cycle. The AD Knowledge Portal initially hosted data from the AcceleratingTHE PSORCAST STUDY
The Psorcast Study will be a remote, nationwide observational study to collect multidimensional, high-resolution time-series data from psoriasis patients’ smartphone sensors. The Psorcast app measures symptoms, disease-influencing factors, and outcomes as a foundational dataset for creating personalized forecasts of disease activity. MULTIPLE MYELOMA DREAM CHALLENGE Multiple myeloma (MM) is a cancer of the plasma cells in the bone marrow, and its clinical course depends on a complex interplay of clinical traits and molecular characteristics of the plasma cells. Since risk-adapted therapy is becoming standard of care, there is an urgent need for a precise risk stratification model to assist inLARA MANGRAVITE
Lara Mangravite, PhD, is President of Sage Bionetworks. Previously, she served as the director of the systems biology research group at Sage, where she focused on the application of collaborative approaches to advance understanding of disease biology and treatment outcomes at a systems level with the overriding goal of improving clinical care. Dr. Mangravite earned PARKINSON’S DISEASE DIGITAL BIOMARKER DREAM CHALLENGE Recent advances in mobile health have demonstrated great potential to leverage sensor-based technologies for remote monitoring of health and disease – particularly for diseases affecting motor function such as Parkinson’s disease (PD). However, converting sensor-based data streams into digital biomarkers is complex and no methodological standards have yet evolved to guide this process. The SAGE BIONETWORKS: RESPONSIBLE DATA SHARING, RELIABLE METHODSABOUTHOW WE PARTNERTOOLS & RESOURCESCAREERSBOARD OF DIRECTORSSCIENTIFICADVISORY BOARD
A suite of web services and tools that make it easier for researchers to aggregate, organize, analyze, and share scientific data, code, and insights. A platform for conducting biomedical research studies primarily using the ResearchKit (iOS) and ResearchStack (Android) frameworks. An open-science, collaborative competition framework forPUBLICATIONS
IRB Management and Function, 3rd edition: mHealth, Mobile Devices, and Apps (book chapter) January 17. Open Data Sharing in the 21st Century: Sage Bionetworks’ Qualified Research Program and Its Application in mHealth Data Release. January 8. Crowdsourced mapping of unexplored target space of kinase inhibitors.OPEN POSITIONS
Sage Bionetworks is a nonprofit research and technology development organization based in Seattle. We have a flat management structure and we offer competitive salaries, comprehensive benefits (health, dental, life and disability, health savings, 403b retirement plan), vacation time, flexible schedule and the ability to work from home, bike facilities, great coffee (we have a La WHO WE ARE - SAGE BIONETWORKS Sage Bionetworks is a nonprofit health research organization that was founded in Seattle in 2009. We use open practices that increase the reliability of scientific claims to speed the translation of science to medicine. We support responsible data sharing, objective evaluation of methods and results across researchers, and the empowerment ofAD KNOWLEDGE PORTAL
The AD Knowledge Portal is a platform for accessing data, analyses, and tools that the National Institute on Aging’s (NIA) Alzheimer’s Disease Translational Research Program generates through several initiatives. The program encourages open-science collaborations that share resources early in the research life cycle. The AD Knowledge Portal initially hosted data from the Accelerating AGORA - SAGE BIONETWORKS Agora hosts evidence for whether or not genes are associated with Alzheimer’s disease (AD). Agora also contains a list of close to 100 nascent drug targets for AD that were nominated. by AD researchers. The initial list of nominated targets was contributed by researchers from the National Institute on Aging’s Accelerating Medicines Partnership in Alzheimer’s TREAT-AD - SAGE BIONETWORKS The overarching purpose of the TREAT-AD program is to improve, diversify and reinvigorate the Alzheimer’s disease (AD) drug development pipeline by accelerating the characterization and experimental validation of next generation therapeutic targets and integrating the targets into drug discovery campaigns. In addition, this program aims to de JUSTIN GUINNEY, VP COMPUTATIONAL ONCOLOGY Justin Guinney is the Vice President of the Computational Oncology group at Sage Bionetworks. His group contains specialists from multiple domains, including molecular biology, computer science, and oncology, and focuses on the development of computational models for optimizing patient diagnosis, prognosis, and treatment in cancer. ELEMENTS OF INFORMED CONSENT The Elements of Informed Consent is a toolkit that will help researchers think through what information participants should receive as part of the consenting process in order to make an informed decision about whether or not to join a study. Developed by the Governance Team at Sage Bionetworks, the toolkit shares basic information and best practices for developing an effective consentingprocess.
DIGITAL MAMMOGRAPHY DREAM CHALLENGE The goal of the Digital Mammography (DM) DREAM Challenge was to apply an open science, crowd-sourced approach to develop and assess algorithms for risk stratification of screening mammograms that can be used to improve breast cancer detection. These algorithms could potentially benefit interpretation of other tumor imaging, impacting a wide set of cancer patients. The SAGE BIONETWORKS: RESPONSIBLE DATA SHARING, RELIABLE METHODSABOUTHOW WE PARTNERTOOLS & RESOURCESCAREERSBOARD OF DIRECTORSSCIENTIFICADVISORY BOARD
A suite of web services and tools that make it easier for researchers to aggregate, organize, analyze, and share scientific data, code, and insights. A platform for conducting biomedical research studies primarily using the ResearchKit (iOS) and ResearchStack (Android) frameworks. An open-science, collaborative competition framework forPUBLICATIONS
IRB Management and Function, 3rd edition: mHealth, Mobile Devices, and Apps (book chapter) January 17. Open Data Sharing in the 21st Century: Sage Bionetworks’ Qualified Research Program and Its Application in mHealth Data Release. January 8. Crowdsourced mapping of unexplored target space of kinase inhibitors.OPEN POSITIONS
Sage Bionetworks is a nonprofit research and technology development organization based in Seattle. We have a flat management structure and we offer competitive salaries, comprehensive benefits (health, dental, life and disability, health savings, 403b retirement plan), vacation time, flexible schedule and the ability to work from home, bike facilities, great coffee (we have a La WHO WE ARE - SAGE BIONETWORKS Sage Bionetworks is a nonprofit health research organization that was founded in Seattle in 2009. We use open practices that increase the reliability of scientific claims to speed the translation of science to medicine. We support responsible data sharing, objective evaluation of methods and results across researchers, and the empowerment ofAD KNOWLEDGE PORTAL
The AD Knowledge Portal is a platform for accessing data, analyses, and tools that the National Institute on Aging’s (NIA) Alzheimer’s Disease Translational Research Program generates through several initiatives. The program encourages open-science collaborations that share resources early in the research life cycle. The AD Knowledge Portal initially hosted data from the Accelerating AGORA - SAGE BIONETWORKS Agora hosts evidence for whether or not genes are associated with Alzheimer’s disease (AD). Agora also contains a list of close to 100 nascent drug targets for AD that were nominated. by AD researchers. The initial list of nominated targets was contributed by researchers from the National Institute on Aging’s Accelerating Medicines Partnership in Alzheimer’s TREAT-AD - SAGE BIONETWORKS The overarching purpose of the TREAT-AD program is to improve, diversify and reinvigorate the Alzheimer’s disease (AD) drug development pipeline by accelerating the characterization and experimental validation of next generation therapeutic targets and integrating the targets into drug discovery campaigns. In addition, this program aims to de JUSTIN GUINNEY, VP COMPUTATIONAL ONCOLOGY Justin Guinney is the Vice President of the Computational Oncology group at Sage Bionetworks. His group contains specialists from multiple domains, including molecular biology, computer science, and oncology, and focuses on the development of computational models for optimizing patient diagnosis, prognosis, and treatment in cancer. ELEMENTS OF INFORMED CONSENT The Elements of Informed Consent is a toolkit that will help researchers think through what information participants should receive as part of the consenting process in order to make an informed decision about whether or not to join a study. Developed by the Governance Team at Sage Bionetworks, the toolkit shares basic information and best practices for developing an effective consentingprocess.
DIGITAL MAMMOGRAPHY DREAM CHALLENGE The goal of the Digital Mammography (DM) DREAM Challenge was to apply an open science, crowd-sourced approach to develop and assess algorithms for risk stratification of screening mammograms that can be used to improve breast cancer detection. These algorithms could potentially benefit interpretation of other tumor imaging, impacting a wide set of cancer patients. ThePUBLICATIONS
IRB Management and Function, 3rd edition: mHealth, Mobile Devices, and Apps (book chapter) January 17. Open Data Sharing in the 21st Century: Sage Bionetworks’ Qualified Research Program and Its Application in mHealth Data Release. January 8. Crowdsourced mapping of unexplored target space of kinase inhibitors. NEWS & PRESS RELEASES 2017. November 3. Sage Bionetworks is part of a consortium of universities and research groups which has received a five-year, $25 million grant from the National Center for Advancing Translational Science. August 21. Novartis launches first large-scale research study in multiple sclerosis that allows participants to contribute fromsmartphones.
TOOLS & RESOURCES
The Platform and Governance teams at Sage Bionetworks work across the organization and beyond to support collaborative research. Whether the projects fall under scientific coordination, challenges and benchmarking, or digital health, the Platform and Governance teams are integral to their success.Because we advocate for open-science practices and improving accessibility to resources, many ofOUR CULTURE
Culture Tenets. People – We embrace our people and who they are.; Team – All of our team members have the opportunity to work across multiple projects and across teams. This gives each of us exposure to the inter-connectivity of our domains and the opportunity to work at the intersection of science, technology, design, governance and ethics; to build skills and a knowledge base outside ofDIGITAL HEALTH
Technology has become a regular part of our everyday lives. Smartphones and other wearable sensors have put touchscreens and high-fidelity sensors into the pockets of billions of people. These technologies provide an opportunity to paint a rich understanding of health and disease in the natural world outside of the clinic. They also provide communication tools SCIENTIFIC COORDINATION As biological research has become more data intensive, the breadth of data and expertise required to address research problems has expanded. In many cases, research problems require the integrated efforts of a distributed set of researchers with shared interests and complementary resources. We work with funders and researchers to coordinate data distribution under FAIR principles ALL OF US RESEARCH PROGRAM The mission of the All of Us Research Program is to accelerate health research and medical breakthroughs, enabling individual prevention, treatment, and care solutions. The Digital Health Technology (DHT) effort within All of Us uses technologies like mobile apps and wearable devices to measure and track aspects of lifestyle, environment, and biology. We design and deploy MULTIPLE MYELOMA DREAM CHALLENGE Multiple myeloma (MM) is a cancer of the plasma cells in the bone marrow, and its clinical course depends on a complex interplay of clinical traits and molecular characteristics of the plasma cells. Since risk-adapted therapy is becoming standard of care, there is an urgent need for a precise risk stratification model to assist inTHE PSORCAST STUDY
The Psorcast Study will be a remote, nationwide observational study to collect multidimensional, high-resolution time-series data from psoriasis patients’ smartphone sensors. The Psorcast app measures symptoms, disease-influencing factors, and outcomes as a foundational dataset for creating personalized forecasts of disease activity. ICGC-TCGA WHOLE GENOME PAN-CANCER ANALYSIS WORKING GROUP In 2013, Sage assisted with the coordination of The Cancer Genome Atlas (TCGA) pan-cancer analysis by hosting and coordinating the outputs of 65 different analytical workflows using the open source software platform developed by Sage, called Synapse, which data scientists can use to carry out, track, and communicate their research in real time. Since then,Skip to content
Menu
Toggle navigation
* About
* Who We Are
* Leadership Team
* Board of Directors * Scientific Advisory Board * News & Press Releases* Get Newsletters
* Events
* Our Projects
* Overview
* Scientific Coordination * Challenges & Benchmarking* Digital Health
* Tools & Resources
* Overview
* Platforms
* Governance
* Careers
* Our Culture
* Our Core Values
* Diversity and Inclusion* Code of Conduct
* Open Positions
* About Sage
* Who We Are
* Our Leadership
* Board of Directors * Scientific Advisory Board * News & Press Releases* Events
* Our Newsletters
* Our Projects
* Overview
* Scientific Coordination * Challenges & Benchmarking* Digital Health
* Tools & Resources
* Overview
* Platforms
* Governance
* Careers
* Our Culture
* Open Positions
BETTER SCIENCE TOGETHER With big data, complex algorithms, and personalized health monitoring, technology has revolutionized the life sciences. But how do we translate these insights into actions? At Sage Bionetworks, we believe that modern science is a team sport. By harnessing the power of open science, we help research communities develop reliable outcomes to advance our understanding of human health.WHAT WE DO
PROMOTE COMMUNITY RESEARCH Sage supports research collaborations by overseeing data coordination, visualization, and analytics across distributed teams. We manage grant- or project-based research consortia to share, evaluate and distribute data, methods, and insights.Learn more
BENCHMARK COMPUTATIONAL METHODS Because we are all susceptible to the self-assessment bias, Sage has developed tools that help researchers to objectively benchmark the performance of computational methods, and to disseminate community-verified methods.Learn more
UNDERSTAND REAL-WORLD EVIDENCE By applying our approach to digital health, Sage works with participants and researchers to understand how real-world environments impact our individual experience of health and disease.Learn more
OUR TOOLS & RESOURCESSynapse
A suite of web services and tools that make it easier for researchers to aggregate, organize, analyze, and share scientific data, code, andinsights.
View Synapse
Bridge
A platform for conducting biomedical research studies primarily using the ResearchKit (iOS) and ResearchStack (Android) frameworks.View Bridge
Challenges
An open-science, collaborative competition framework for evaluating and comparing computational algorithms.View Challenges
Governance
Resources and policies including novel approaches to informed consent, clinical protocols, and data access.View Governance
More Tools & ResourcesLATEST NEWS
Challenges & BenchmarkingPRESS RELEASE
Combining Artificial Intelligence with Assessments from Radiologists Could Help Improve Accuracy of Mammography Screenings SEATTLE, March 2, 2020 – In a study published today in...View full post
Publications
UNCOVERING THERAPEUTIC STRATEGIES FOR NEUROFIBROMATOSIS TYPE 1 Drug discovery studies are challenging to conduct for rare diseases because there often isn’t enough relevant biological data. Small, or underpowered, datasets hinder the effectiveness...View full post
Publications
SAGE PERSPECTIVE: RETENTION IN REMOTE DIGITAL HEALTH STUDIES Editor’s note: This is a Twitter thread from John Wilbanks, Sage’s chief commons officer. New from Abishek Pratap and a few more ofus...
View full post
Copyright © 2020 Sage Bionetworks Conflict of Interest Policy* Events
* News
* Publications
* Contact
* __
* __
* __
* Events
* News
* Publications
* Contact
Copyright © 2020 Sage Bionetworks Conflict of Interest Policy* __
* __
* __
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0